For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Pacific Biosciences of California Inc’s stock clocked out at $1.55, up 6.16% from its previous closing price of $1.46. In other words, the price has increased by $6.16 from its previous closing price. On the day, 16.79 million shares were traded. PACB stock price reached its highest trading level at $1.67 during the session, while it also had its lowest trading level at $1.435.
Ratios:
To gain a deeper understanding of PACB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.81. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on April 18, 2024, Downgraded its rating to Neutral and sets its target price to $2.50 from $7 previously.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $11.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 06 ’24 when Meline David W bought 40,000 shares for $4.40 per share. The transaction valued at 176,160 led to the insider holds 40,000 shares of the business.
HENRY CHRISTIAN O sold 14,177 shares of PACB for $69,056 on Mar 04 ’24. The insider now owns 2,596,670 shares after completing the transaction at $4.87 per share. On Mar 04 ’24, another insider, Van Oene Mark, who serves as the insider of the company, sold 9,186 shares for $4.87 each. As a result, the insider received 44,745 and left with 1,668,826 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 415325600 and an Enterprise Value of 714839424. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.10 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at 3.565 whereas that against EBITDA is -2.489.
Stock Price History:
Over the past 52 weeks, PACB has reached a high of $14.55, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -64.14%, while the 200-Day Moving Average is calculated to be -80.87%.
Shares Statistics:
It appears that PACB traded 9.61M shares on average per day over the past three months and 17793820 shares per day over the past ten days. A total of 267.74M shares are outstanding, with a floating share count of 255.73M. Insiders hold about 6.08% of the company’s shares, while institutions hold 101.19% stake in the company. Shares short for PACB as of 1711584000 were 49049700 with a Short Ratio of 5.10, compared to 1709164800 on 43538338. Therefore, it implies a Short% of Shares Outstanding of 49049700 and a Short% of Float of 20.29.
Earnings Estimates
The current assessment of Pacific Biosciences of California Inc (PACB) involves the perspectives of Aurora Cannabis Inc. analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $1.55, with high estimates of $2.12 and low estimates of $7.19.
